Sumitomo Mitsui Asset Management Company LTD decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 94,334 shares of the biopharmaceutical company’s stock after selling 5,539 shares during the quarter. Sumitomo Mitsui Asset Management Company LTD’s holdings in Gilead Sciences were worth $6,758,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of GILD. Capital International Investors increased its holdings in shares of Gilead Sciences by 86.6% during the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Sanders Capital LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $427,585,000. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Gilead Sciences by 230.0% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after acquiring an additional 3,434,450 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Gilead Sciences by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Gilead Sciences by 84.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock worth $446,197,000 after acquiring an additional 2,524,657 shares during the last quarter. 75.71% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $78.73 on Thursday. The firm has a market capitalization of $102,820.00, a price-to-earnings ratio of 10.24, a PEG ratio of -1.85 and a beta of 1.22. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.90%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 27.05%.
In other news, EVP Gregg H. Alton sold 14,435 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 432,768 shares of company stock valued at $33,919,138. Corporate insiders own 1.30% of the company’s stock.
A number of research firms recently weighed in on GILD. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 target price on the stock. in a report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley decreased their target price on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Bank of America boosted their target price on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a report on Thursday, February 8th. Thirteen equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $86.92.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.